Fate Therapeutics (FATE) PT Raised to $40 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
Go back to Fate Therapeutics (FATE) PT Raised to $40 at Oppenheimer
June 10, 2020 7:51 AM EDT
Guggenheim analyst Michael Schmidt raised the price target on Fate Therapeutics (NASDAQ: FATE) to $45.00 (from $43.00) while maintaining a Buy rating after the company provided a portfolio-wide clinical update. The update was part of the SEC filings for FATE's capital raise.
Guggenheim... More
June 9, 2020 5:53 AM EDT
Fate Therapeutics, Inc. (NASDAQ: FATE) today announced the pricing of an underwritten public offering of 6,181,562 shares of its common stock at a public offering price of $28.31 per share, before underwriting discounts, for an aggregate offering of approximately $175 million. Fate Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 927,234 shares of its common stock. The proceeds to Fate Therapeutics from this offering are expected... More
June 8, 2020 4:03 PM EDT
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that it has commenced an underwritten public offering of its common stock. Fate Therapeutics intends to use the net proceeds from the offering to fund clinical trials and nonclinical studies, the manufacture of its clinical product candidates, the expansion of its cGMP compliant manufacturing operations, including the construction,... More
